Naseema Gangat/mayoclinic.org
Dec 23, 2024, 13:42
Pre-treatment and response-based prognostic tools for newly diagnosed AML – American Journal of Hematology
American Journal of Hematology shared a post on X:
“The Mayo genetic risk models offer pre-treatment and response-based prognostic tools for newly diagnosed AML treated with Ven-HMA.”
Authors: Naseema Gangat et al.
Aasiya Matin
Abhishek Mangaonkar
Abigail Sneider
Acute Myeloid Leukaemia (AML)
Alex Bataller
Alexandre Bazinet
American Journal of Hematology
Anand A. Patel
Animesh Pardanani
Antoine N Saliba
Aref Al-Kali
Ayalew Tefferi
Azeem Elbeih
cancer
Cecilia Arana-Yi
Courtney DiNardo
Emily Dworkin
Fnu Aperna
Hassan B. Alkhateeb
Hemant Murthy
Hematology
Isla M. Johnson
James Foran
Jayastu Senapati
Jeanne Palmer
Kebede H Begna
Kristen McCullough
Lisa Sproat
Mark R Litzow
Maymona Abdelmagid
Mehrdad Hefazi Torghabeh
Michelle Elliott
Mithun Shah
Mrinal M Patnaik
Nandita Khera
Naseema Gangat
Nour Ghosoun
OncoDaily
Oncology
Samuel Yates
Talha Badar
Tapan Kadia
William Hogan
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 23, 2024, 13:24
Dec 23, 2024, 13:06
Dec 23, 2024, 12:55
Dec 23, 2024, 12:47
Dec 23, 2024, 12:47
Dec 23, 2024, 12:45